NasdaqGS:SRRKBiotechs
Scholar Rock (SRRK) Valuation: Assessing Share Price After Pivotal Apitegromab Results and FDA Priority Review
If you are watching Scholar Rock Holding (SRRK), this week’s news probably caught your eye. Shares surged 14% right after the company published positive Phase 3 SAPPHIRE trial results for its SMA therapy, apitegromab, in The Lancet Neurology. The data shows real motor function improvements in children and adults with spinal muscular atrophy, which is a significant development for families and clinicians seeking new options. Just as important, the FDA has now accepted the company’s Biologics...